International Journal of Infectious Diseases最新文献

{"title":"A rapid and sensitive extraction-free HiFi-LAMP assay for detecting Mycobacterium leprae.","authors":"Zhengfang Wang, Xi Yang, Zhi-Ze Wang, Xiu-Feng Yu, Zhe Li, Shangwen Song, Yongjuan Zhao, Yi-Qun Kuang, Yu-Ye Li, Chiyu Zhang","doi":"10.1016/j.ijid.2025.107835","DOIUrl":"https://doi.org/10.1016/j.ijid.2025.107835","url":null,"abstract":"<p><strong>Background: </strong>Timely and accurate detection of Mycobacterium leprae (M. leprae) is crucial for efficient treatment and early intervention of leprosy, which requires a simple and rapid extraction-free assay.</p><p><strong>Methods: </strong>An HiFi-LAMP assay was developed for detection of M. leprae. The performance of the assay was assessed by comparing with qPCR and nested PCR assays using clinical samples. The extraction-free HiFi-LAMP assay was assessed by saliva from individuals with leprosy.</p><p><strong>Results: </strong>The M. leprae HiFi-LAMP assay has high specificity and sensitivity with a limit of detection (LOD) of 43 copies/25 μL reaction. Both sensitivity and specificity of the assay were 100% for 130 purified DNA from nasal and oral samples, and the sensitivity was slightly higher than 50-88.9% by the qPCR assay. A higher detection rate of M. leprae was observed in nasal swabs than oral swabs. The extraction-free assay directly using 6 μL saliva that has a LOD of 11,833 M. leprae RLEP copies/mL saliva can be completed within 30 mins, and showed 66.7% sensitivity for three saliva samples when compared with the assay using purified DNA.</p><p><strong>Conclusion: </strong>The standard and/or extraction-free HiFi-LAMP assays can be used for detecting and monitoring M. leprae in endemic areas in resource-limited settings.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107835"},"PeriodicalIF":4.8,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of extended anaerobic antibiotic coverage on anaerobic bloodstream infection: A multisite retrospective study.","authors":"Y Murai, K Nagaoka, N Iwanaga, H Kawasuji, M Miura, Y Sato, Y Hatakeyama, Y Kato, T Takazono, K Kosai, A Sugano, Y Morinaga, K Tanaka, K Yanagihara, H Mukae, Y Yamamoto","doi":"10.1016/j.ijid.2025.107840","DOIUrl":"https://doi.org/10.1016/j.ijid.2025.107840","url":null,"abstract":"<p><strong>Objective: </strong>Routine clinical practice with extended anaerobic antibiotic coverage (EAC) has been recently reconsidered for several infections; however, its benefits remain unclear even in patients with anaerobic bacteremia (AB). Here, we aimed to elucidate the effects of EAC on AB prognosis.</p><p><strong>Methods: </strong>A multicenter retrospective observational study was conducted in patients with AB. Multivariate logistic regression analysis was performed to assess the effect of EAC on 30-day mortality. Inverse probability of treatment weighting analysis was performed to confirm the robustness of the findings.</p><p><strong>Results: </strong>In total, 483 patients were included, of whom 387 received EAC and 96 received limited anaerobic antibiotic coverage (LAC). Atypical foci of anaerobic infection, such as urinary tract infection and pneumonia, together with undetectable infection foci, comprised a larger proportion of infection foci in the LAC group than that in the EAC group (46.9% vs. 30.5%). The 30-day mortality rates of the EAC and LAC groups were similar (12.5% and 14.2%, respectively; p=0.664). Primary analysis revealed that EAC was not significantly associated with high mortality (odds ratio [OR], 1.42; 95% confidence interval [CI], 0.7-2.8), whereas source control significantly reduced this risk (OR, 0.28; 95% CI, 0.2-0.5). The sensitivity analysis results were consistent with those of the primary analyses.</p><p><strong>Conclusions: </strong>This study demonstrated a less significant effect of initial EAC on AB compared with source control, particularly on AB with atypical infection foci. These findings would prompt reconsideration of the necessity of an initial EAC in several infections.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107840"},"PeriodicalIF":4.8,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphatic Filariasis Elimination in Kenya: Tracing the Journey from 2002 - 2024 and Pathways to Achieving 2030 Target.","authors":"Michael Ofire Ofire, Victor Omanje, Ivy Sempele, Irene Chami, Patrick Ngotho Gitahi, Sammy M Njenga, Wyckliff Peter Omondi","doi":"10.1016/j.ijid.2025.107839","DOIUrl":"https://doi.org/10.1016/j.ijid.2025.107839","url":null,"abstract":"<p><p>Lymphatic filariasis (LF) is a parasitic neglected tropical disease (NTD) that can lead to debilitating conditions such as lymphoedema (elephantiasis) and hydrocele, impacting affected individuals' quality of life and economic productivity by interfering with their physical and psychological health. Like most countries, Kenya established its National Programme to Eliminate Lymphatic Filariasis in 2000. It launched its first Mass Drug Administration (MDA) in Kilifi District in 2002, with subsequent expansions to Kwale, Malindi, Tana River, Lamu, and Mombasa counties in Kenya's coastal region. This is despite documenting its first case in 1910, with high antigenemia and microfilariae prevalence reported by most studies conducted in the pre-program period. MDA was implemented intermittently from 2000 to 2015 due to limited resources to treat all at-risk individuals. However, since 2016, the country has implemented continuous and successive MDA campaigns, which have contributed to a significant reduction in disease prevalence based on the results of transmission and impact surveys conducted so far. Therefore, it is plausible to envisage that the country is on track toward eliminating LF as a public health problem in Kenya by 2030.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107839"},"PeriodicalIF":4.8,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unseasonal respiratory syncytial virus epidemics during the COVID-19 pandemic: relationship between climatic factors and epidemic strain switching.","authors":"Akira Shinzato, Kenji Hibiya, Naoya Nishiyama, Nanae Ikemiyagi, Wakako Arakaki, Wakaki Kami, Daijiro Nabeya, Shuhei Ideguchi, Hideta Nakamura, Makoto Furugen, Kazuya Miyagi, Masashi Nakamatsu, Shusaku Haranaga, Takeshi Kinjo, Jiro Fujita, Koshi Nakamura, Kazuko Yamamoto","doi":"10.1016/j.ijid.2025.107833","DOIUrl":"https://doi.org/10.1016/j.ijid.2025.107833","url":null,"abstract":"<p><strong>Objectives: </strong>The coronavirus disease (COVID-19) pandemic affected respiratory syncytial virus (RSV) epidemic patterns. However, effects of climatic and virological factors on RSV epidemics remain poorly understood. We investigated the incidence of RSV infection in Okinawa, Japan; Taiwan, China; and Florida, USA before and after the COVID-19 pandemic, focusing on the effects of population mobility and climate.</p><p><strong>Methods: </strong>We investigated correlations between RSV incidence, human mobility, and climate, pre- and post-pandemic. The second variable region of RSV G proteins was analysed phylogenetically using viral genomes isolated from patients in Okinawa with acute respiratory-tract infections.</p><p><strong>Results: </strong>Annual RSV epidemics in Okinawa were not correlated with human mobility post-pandemic. The temperature and humidity zones at the RSV epidemic onset differed between pre- and post-pandemic periods; the respective standard deviations decreased. Genetic analysis of RSV strains from 2020 to 2022 revealed a cluster with low genetic diversity, markedly different from pre-2019 or 2023 prevalent strains.</p><p><strong>Conclusions: </strong>Reduced human migration led to an RSV epidemic caused by an indigenous endemic strain, demonstrating the natural relationship between the epidemic and climatic factors. These findings could help develop effective prediction and control programs for RSV epidemics and inform the development of an effective vaccine program.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107833"},"PeriodicalIF":4.8,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the Guidelines: Original Research on Real-World Outcomes of Anticoagulation and Corticosteroid in COVID-19.","authors":"Alison Leslie, Scott A Chapman, Katelyn M Tessier, Christopher Tignanelli, Sameh Hozayen","doi":"10.1016/j.ijid.2025.107834","DOIUrl":"https://doi.org/10.1016/j.ijid.2025.107834","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic has led to the widespread use of anticoagulation (AC) and corticosteroids (CCS) for hospitalized patients, but real-world outcomes may differ from clinical trial findings due to diverse patient populations and treatment variability.</p><p><strong>Objective: </strong>To evaluate the real-world impact of AC and CCS therapies on key clinical outcomes in hospitalized COVID-19 patients.</p><p><strong>Design: </strong>Multicenter, retrospective observational cohort study conducted across 11 hospitals in a Midwest health system.</p><p><strong>Participants: </strong>The study included 4,754 hospitalized COVID-19 patients treated with AC, CCS, both (AC+CCS), or neither. The 'neither' group served as the reference for comparisons.</p><p><strong>Interventions: </strong>Interventions included administration of AC, CCS, both AC+CCS, or no intervention.</p><p><strong>Main measures: </strong>Primary outcomes included thromboembolism (TE), bleeding events, ICU admissions, invasive mechanical ventilation (IMV), and in-hospital mortality.</p><p><strong>Key results: </strong>Compared to the reference group, the AC+CCS group had significantly lower odds of TE (aOR 0.61, 95% CI 0.43-0.87) and bleeding events (aOR 0.15 95% CI (0.08, 0.27)). The AC-only group demonstrated the lowest ICU admission, IMV, and mortality rates (aHR 0.30 95% CI (0.17, 0.53)). The CCS-only group had the highest rates of adverse outcomes, likely reflecting greater baseline illness severity.</p><p><strong>Conclusions: </strong>This study emphasizes the importance of individualized treatment strategies in hospitalized COVID-19 patients, showing that real-world outcomes of AC and CCS can differ significantly from controlled trials. These findings provide crucial insights for adapting clinical guidelines to diverse patient settings.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107834"},"PeriodicalIF":4.8,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and evaluation of blood transcriptional biomarker for tuberculosis screening.","authors":"Siqi Zhang, Cheng Bei, Meng Li, Jianfeng Zeng, Liangzi Yang, TanTan Ren, Guofang Deng, Ruimin Hong, Juanjia Cai, Dan Li, Chuan Wang, Peng Xu, Howard Takiff, Shuihua Lu, Peize Zhang, Qian Gao","doi":"10.1016/j.ijid.2025.107838","DOIUrl":"https://doi.org/10.1016/j.ijid.2025.107838","url":null,"abstract":"<p><strong>Objectives: </strong>Non-sputum-based screening methods for active case finding are a priority for ending tuberculosis. We sought to identify and evaluate blood transcriptional biomarkers suitable for tuberculosis screening.</p><p><strong>Methods: </strong>We integrated five blood RNA-seq datasets from global tuberculosis patients and identified genes that are differentially expressed between tuberculosis patients and healthy controls, using resampling and exhaustive testing. Three candidate biomarker combinations were identified from seven microarray datasets and small-scale clinical samples. The performance of these combinations for screening was evaluated in a cohort of close contacts of pulmonary tuberculosis (PTB) patients, and the results compared with Xpert HR.</p><p><strong>Results: </strong>We identified three 3-gene biomarker combinations, each containing two upregulated genes (FCGR1A, BATF2, or GBP5) and one downregulated gene (KLF2), and used these combinations to screen 352 close contacts of PTB. The biomarker combinations distinguished confirmed PTB patients from other participants with AUCs ranging from 0.848 to 0.870. With specificity fixed at 70%, all three combinations showed sensitivities of 87.5%. In a cohort of 205 presumptive pulmonary tuberculosis patients, the AUCs for distinguishing confirmed tuberculosis patients from other diseases ranged from 0.784 to 0.806. At 70% specificity, sensitivities were 75.9% to 81.5%, and were significantly higher with larger sputum bacterial loads. The performances of the three combinations for tuberculosis screening or diagnosis were comparable to Xpert HR.</p><p><strong>Conclusion: </strong>The three transcriptomic biomarkers identified in this study performed well for tuberculosis screening, nearly meeting the minimum WHO benchmarks for a triage test and showed potential utility in the development of new screening tools.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107838"},"PeriodicalIF":4.8,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rise and fall of the Myth of the Good Pathogen in Evolutionary Biology and Medicine.","authors":"Fabio Zampieri, Fabio Michieletto, Alberto Zanatta","doi":"10.1016/j.ijid.2025.107836","DOIUrl":"https://doi.org/10.1016/j.ijid.2025.107836","url":null,"abstract":"<p><p>The history of the conceptions of evolution of virulence is well known. However, in this period following the Covid-19 pandemic, it may be useful to recap such a current topic. In the public debate, it has often been heard that the Covid-19 was destined to evolve into a less virulent form, because it would be in the virus's interest to coexist with the human population. This concept can be defined as the \"Myth of the good pathogen\" and originated from Smith's \"law of declining virulence\". The successes achieved thanks to vaccinations and antibiotics led the medical community, between the 1940s and 1970s, to argue that the battle against infectious diseases had been won. However, the AIDS pandemic brought back down to earth the scientific community in their speculations about plagues. Since 1970s, biologists have advanced the \"virulence transmission trade-offs theory\", a new model according to which intermediate virulence maximizes pathogenicity as a result of a trade-off between virulence and transmission. The introduction of trade-off models represented a crucial change that replaced the binary logic according to which natural selection shaped adaptations, while maladaptation escaped selection. This change was fundamental for the introduction of a new perspective in medicine, namely Evolutionary Medicine, which might be an essential tool not only for understanding the dynamics of epidemics, but also for preventing and curing infectious diseases.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107836"},"PeriodicalIF":4.8,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influenza and pneumococcal vaccine coverage among adults hospitalised with acute respiratory infection in France: a prospective cohort study.","authors":"S Rolland, Lb Luong Nguyen, A Descamps, F Galtier, X Duval, P Vanhems, F Lainé, P Tattevin, R Bauer, O Launay","doi":"10.1016/j.ijid.2025.107811","DOIUrl":"https://doi.org/10.1016/j.ijid.2025.107811","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to estimate influenza and pneumococcal vaccination coverage (VC) among adults hospitalised with severe acute respiratory infections (SARI) in France from 2016 to 2022 and to analyse factors associated with vaccination.</p><p><strong>Methods: </strong>We analysed data from a prospective multicentre study, in adults hospitalised with SARI. A descriptive and comparative analysis of influenza and pneumococcal VCs was conducted, along with multivariate logistic regression to identify factors associated with vaccination.</p><p><strong>Results: </strong>We included 4614 patients; 88% (4080/4614) had an indication for influenza vaccination. Among them, 2181/4080 (53%) were vaccinated against influenza. Factors associated with vaccination included age ≥65 years (adjusted odds ratio [aOR] 3.05; 95% CI 2.63 - 3.55), chronic respiratory diseases (aOR 1.38; 95% CI 1.20 - 1.59). Pneumococcal vaccination status was available for 90% (4142/4614) patients, among whom 71% (2920/4142) had an indication for vaccination. Pneumococcal VC was 19% (551/2920). Factors associated with vaccination were chronic respiratory disease (aOR 2.74; 95% CI 2.22 - 3.40) and immunocompromising conditions other than malignancies. VC for each vaccine did not increase overtime. Among 3247 patients eligible for both vaccines 13% received both.</p><p><strong>Conclusion: </strong>In this high-risk population, VC was low, especially pneumococcal vaccines. Improved vaccination recommendation strategies and communication are needed.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107811"},"PeriodicalIF":4.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tuberculosis infection prevalence and treatment completion among refugees in the United States","authors":"Dan Shen ,&nbsp;Aurimar Ayala ,&nbsp;Randall Reves ,&nbsp;Michelle Haas ,&nbsp;Renuka Khurana ,&nbsp;Tuberculosis Epidemiologic Studies Consortium","doi":"10.1016/j.ijid.2024.107361","DOIUrl":"10.1016/j.ijid.2024.107361","url":null,"abstract":"<div><h3>Background</h3><div>Identifying and treating tuberculosis infection (TBI) among refugees at elevated risk for developing TB disease is crucial for TB prevention and elimination in the United States (U.S.). However, current evidence is limited by small sample sizes, inclusion of refugees from only a single country, and/or reliance solely on the tuberculin skin test (TST).</div></div><div><h3>Methods</h3><div>Refugees in a large cohort study from 10 U.S. sites underwent evaluation for TBI using three available tests: the TST and two interferon-gamma release assays (IGRAs). This study calculated TBI prevalence and assessed tuberculosis preventive treatment (TPT) completion among refugees, defining TBI prevalence as positive results on at least two tests.</div></div><div><h3>Results</h3><div>Among 8960 refugees enrolled July 2012 through May 2017, TBI prevalence was 23.2% (95% confidence interval [CI]: 22.4%-24.1%). Completion of TPT was 81.2% (95% CI: 79.6%-82.7%). Shorter treatment regimens of 3 months were associated with higher treatment completion compared to regimens of 6 months or longer.</div></div><div><h3>Conclusion</h3><div>The high TBI prevalence among refugees is a concern, but their high TPT acceptance and completion rates offer an opportunity. IGRA-based tests are preferred in this population; however, limited resources underscore the need for more precise screening approaches to better identify high-risk individuals who truly require TPT.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107361"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recombinase polymerase amplification technology for point-of-care diagnosis of neglected tropical diseases.","authors":"Luisa Hueso, Sara Martorell, Amadeo Sena-Torralba, Maite Ferrando, Mireia Ferri, Angel Maquieira, Francine Ntoumi, Sergi Morais","doi":"10.1016/j.ijid.2025.107831","DOIUrl":"https://doi.org/10.1016/j.ijid.2025.107831","url":null,"abstract":"<p><p>Recombinase Polymerase Amplification (RPA) technology significantly advances the diagnostics of neglected tropical diseases (NTDs), providing rapid, isothermal, and minimally preparative testing ideally suited for under-resourced countries. This review critically assesses the current applications, limitations, and potential of RPA for detecting a broad spectrum of NTD pathogens, including viruses, bacteria, helminths, and fungi. The ability of RPA to operate under constant temperature conditions without the need for complex thermal cycling facilitates rapid pathogen detection within minutes, enhancing its utility for decentralized point-of-care testing in remote and underserved regions. RPA, however, faces limitations, including the labor-intensive and costly validation of primer design, especially for multiplex assays, and a susceptibility to non-specific amplification. These challenges highlight the need for continuous refinement to ensure reliable and consistent performance across diverse environmental conditions. Despite these constraints, the scalability of RPA assays and their compatibility with portable detection platforms make them well-suited for deployment in field settings without access to traditional laboratory infrastructure. This review emphasizes the transformative potential of RPA in NTD diagnostics, enhancing accessibility, precision, and timeliness of interventions, ultimately contributing to improved global public health outcomes.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107831"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}